pharmaceutical operations. DFB has realized more than $1.5 billion from the growth and sale of companies in pharmaceutical contract development and manufacturing, dermatology, and wound care. Today, they embrace that same entrepreneurial spirit to identify, invest in, and develop new products and businesses. Collaborating with corporate partners, academic institutions, clinical experts, and other investor groups, their business model enables us to remain entrepreneurial and flexible to solve critical unmet healthcare needs and build value in turn.